Vireo Growth (VREOF) Current Assets (2020 - 2026)
Vireo Growth (VREOF) posted Current Assets of $258.3 million for Q1 2026, down 15.34% sequentially from $305.1 million in Q4 2025, and up 13.07% YoY from $228.4 million in Q1 2025.
Vireo Growth (VREOF) Current Assets (2020 - 2026) Analysis & Trends
Vireo Growth has reported Current Assets for 7 years, with the latest figure at $258.3 million in Q1 2026.
- Quarterly Current Assets rose 13.07% year-over-year to $258.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258.3 million (up 13.07% YoY) and the FY2025 annual result came in at $305.1 million, up 32.44% from the prior year.
- Current Assets declined to $258.3 million in Q1 2026 per VREOF's latest filing, from $305.1 million in the prior quarter.
- Over five years, Current Assets peaked at $312.8 million in Q2 2025 and troughed at $38.8 million in Q1 2022.
- A 5-year average of $164.4 million and a median of $147.2 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets tumbled 33.89% in 2022, then surged 218.55% in 2023.
- Over 5 years, Current Assets stood at $46.7 million in 2022, then soared by 218.55% to $148.9 million in 2023, then surged by 54.77% to $230.4 million in 2024, then jumped by 32.44% to $305.1 million in 2025, then fell by 15.34% to $258.3 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $258.3 million, $305.1 million, and $308.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 3.22 Bn |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 394.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258.30 Mn |
| Dec 31, 2025 | 305.10 Mn |
| Sep 30, 2025 | 307.96 Mn |
| Jun 30, 2025 | 312.79 Mn |
| Mar 31, 2025 | 228.43 Mn |
| Dec 31, 2024 | 230.37 Mn |
| Sep 30, 2024 | 143.96 Mn |
| Jun 30, 2024 | 148.63 Mn |
| Mar 31, 2024 | 147.18 Mn |
| Dec 31, 2023 | 148.85 Mn |
| Sep 30, 2023 | 135.11 Mn |
| Jun 30, 2023 | 126.37 Mn |
| Mar 31, 2023 | 115.56 Mn |
| Dec 31, 2022 | 46.73 Mn |
| Sep 30, 2022 | 53.86 Mn |
| Jun 30, 2022 | 46.39 Mn |
| Mar 31, 2022 | 38.75 Mn |
| Dec 31, 2021 | 41.64 Mn |
| Sep 30, 2021 | 44.75 Mn |
| Jun 30, 2021 | 41.96 Mn |